Drug-eluting stents articles

In diabetic patients, Everolimus eluting stents could perform better than Paclitaxel eluting stents

In diabetic patients, Everolimus eluting stents could perform better than Paclitaxel eluting stents

Original title: Safety and Efficacy of Everolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in a Diabetic Population Reference: Ana Laynez et, al. Catheterization and Cardiovascular Intervention 81:759-765 (2013) Everolimus eluting stents have already been compared with paclitaxel eluting stents in the general population, and they have proved to perform best, especially as regards revascularization and in-stent thrombosis.  However, these data

Strategies for treating left coronary trunk restenosis.

Original title: Clinical and Procedural Predictors of Suboptimal Outcome After the Treatment of Drug-Eluting Stent Restenosis in the Unprotected Distal Left Main Stem The Milan and New-Tokyo (MITO) Registry. Reference: Circ Cardiovasc Interv. 2012;5: 491-498 We have very little data on the percutaneous treatment of restenosis of an unprotected LMCA.  The aim of this study was to evaluate

A new paradigm in the treatment of in-stent restenosis?

Original title: ISAR DESIRE 3: Drug-eluting balloon is best option for restenosis of limus-eluting stents Reference: Dr Robert Byrne. TCT 2012. Miami, Fl. The first of the ISAR DESIRE trials showed that drug-eluting stents (DES) were the best strategy for treating restenosis of a bare metal stent, the second ISAR DESIRE trial tested the hypothesis of changing or

Future second-generation stents, today.

Original title: First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold A Multi-Imaging Modality Study. Reference: John Ormiston et al. Circ Cardiovasc Interv. 2012;5:620-632. The first bioabsorbable stents eluting everolimus showed a 6-month delayed recoil resulting in late lumen loss of 0.44 mm, (intermediate between a metal stent

Drug-Eluting Stents: device without polymers overcomes limitations of first generations stents

The NEXT randomized trial showed the superiority of a polymer-free amphilimus-eluting stent compared to paclitaxel-eluting stents with permanent polymers The NEXT clinical trial (International Randomized Comparison Between DES Limus Carbostent and Taxus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions), is a multicenter randomized trial (n=296) comparing coronary amphilimus eluting stent Cre8 (CID,